Importance of lipid accumulation product index as a marker of CVD risk in PCOS women

Lipids Health Dis. 2015 Jun 24:14:62. doi: 10.1186/s12944-015-0061-y.

Abstract

Background: The polycystic ovary syndrome (PCOS) is considered the most common endocrine disease during the woman's reproductive life, with prevalence ranging from 5 to 10% of women of reproductive age. There is a paucity of studies regarding the use of the lipid accumulation product (LAP) as a risk marker for the development of cardiovascular disease (CVD).

Methods: A cross-sectional study was conducted on 78 women aged 18 to 42 years seen at University Hospital of Maranhão, with a diagnosis of polycystic ovary syndrome according to the Rotterdam criteria. The following variables of interest were recorded on a protocol form: sociodemographic and behavioral data, body mass index, waist circumference, fasting glucose, total cholesterol, triglycerides, low density lipoprotein cholesterol, high-density lipoprotein cholesterol, and systolic and diastolic blood pressure.

Results: Logistic regression showed that, except for HDL, all cardiovascular risk markers presented a higher chance of being altered when the lipid accumulation product was above the cut off value of 37.9 cm.mmol/L.

Conclusion: The lipid accumulation product seems to be sufficient to indicate a risk of cardiovascular diseases in women with polycystic ovary syndrome.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Biomarkers / metabolism*
  • Cardiovascular Diseases / complications*
  • Cardiovascular Diseases / metabolism*
  • Demography
  • Female
  • Humans
  • Lipid Accumulation Product*
  • Logistic Models
  • Polycystic Ovary Syndrome / complications*
  • Polycystic Ovary Syndrome / metabolism*
  • ROC Curve
  • Risk Factors
  • Young Adult

Substances

  • Biomarkers